Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions.

Mao J, Mohutsky MA, Harrelson JP, Wrighton SA, Hall SD.

Drug Metab Dispos. 2012 Apr;40(4):706-16. doi: 10.1124/dmd.111.043158. Epub 2012 Jan 6.

2.

Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma.

Mao J, Mohutsky MA, Harrelson JP, Wrighton SA, Hall SD.

Drug Metab Dispos. 2011 Apr;39(4):591-602. doi: 10.1124/dmd.110.036400. Epub 2011 Jan 6.

3.
4.

In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.

Pan Y, Abd-Rashid BA, Ismail Z, Ismail R, Mak JW, Pook PC, Er HM, Ong CE.

J Ethnopharmacol. 2010 Jul 20;130(2):275-83. doi: 10.1016/j.jep.2010.05.002. Epub 2010 May 8.

PMID:
20457244
5.
6.

Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.

McGinnity DF, Berry AJ, Kenny JR, Grime K, Riley RJ.

Drug Metab Dispos. 2006 Aug;34(8):1291-300. Epub 2006 May 5.

7.

Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.

Xu L, Chen Y, Pan Y, Skiles GL, Shou M.

Drug Metab Dispos. 2009 Dec;37(12):2330-9. doi: 10.1124/dmd.108.025494. Epub 2009 Sep 22.

8.
9.

Database analyses for the prediction of in vivo drug-drug interactions from in vitro data.

Ito K, Brown HS, Houston JB.

Br J Clin Pharmacol. 2004 Apr;57(4):473-86. Review. Erratum in: Br J Clin Pharmacol. 2004 Nov;58(5):565-8.

10.

In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.

Prueksaritanont T, Kuo Y, Tang C, Li C, Qiu Y, Lu B, Strong-Basalyga K, Richards K, Carr B, Lin JH.

Drug Metab Dispos. 2006 Sep;34(9):1546-55. Epub 2006 Jun 16.

12.

Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.

Lu C, Balani SK, Qian MG, Prakash SR, Ducray PS, von Moltke LL.

J Pharmacol Exp Ther. 2010 Feb;332(2):562-8. doi: 10.1124/jpet.109.161893. Epub 2009 Nov 4.

13.

Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.

Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH.

Biopharm Drug Dispos. 2000 Dec;21(9):353-64.

PMID:
11523064
14.

Functional consequences of active hepatic uptake on cytochrome P450 inhibition in rat and human hepatocytes.

Grime K, Webborn PJ, Riley RJ.

Drug Metab Dispos. 2008 Aug;36(8):1670-8. doi: 10.1124/dmd.108.021055. Epub 2008 May 12.

15.

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.

Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM.

J Pharmacol Exp Ther. 2006 Jan;316(1):336-48. Epub 2005 Sep 28.

16.

Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.

Lu C, Hatsis P, Berg C, Lee FW, Balani SK.

Drug Metab Dispos. 2008 Jul;36(7):1255-60. doi: 10.1124/dmd.107.018796. Epub 2008 Apr 1.

17.

Evaluation of cytochrome P450-mediated drug-drug interactions based on the strategies recommended by regulatory authorities.

Kosugi Y, Hirabayashi H, Igari T, Fujioka Y, Hara Y, Okuda T, Moriwaki T.

Xenobiotica. 2012 Feb;42(2):127-38. doi: 10.3109/00498254.2011.626087. Epub 2011 Nov 5.

PMID:
22117526
18.

A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.

Lu C, Miwa GT, Prakash SR, Gan LS, Balani SK.

Drug Metab Dispos. 2007 Jan;35(1):79-85. Epub 2006 Oct 4.

19.

In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran.

Paris BL, Ogilvie BW, Scheinkoenig JA, Ndikum-Moffor F, Gibson R, Parkinson A.

Drug Metab Dispos. 2009 Oct;37(10):2045-54. doi: 10.1124/dmd.109.028274. Epub 2009 Jul 16.

20.

Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.

Sauer JM, Long AJ, Ring B, Gillespie JS, Sanburn NP, DeSante KA, Petullo D, VandenBranden MR, Jensen CB, Wrighton SA, Smith BP, Read HA, Witcher JW.

J Pharmacol Exp Ther. 2004 Feb;308(2):410-8. Epub 2003 Nov 10.

Supplemental Content

Support Center